Myasthenia gravis and lambert-eaton myasthenic syndrome

CONTINUUM Lifelong Learning in Neurology

Volumn 20, Issue 5, 2014, Pages 1413-1425

  Sanders, Donald B ^a   Guptill, Jeffrey T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFAMPRIDINE; AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDOSTIGMINE; RITUXIMAB; STEROID;

COST; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EATON LAMBERT SYNDROME; ELECTROMYOGRAPHY; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PLASMA EXCHANGE; QUALITY OF LIFE; REVIEW; THYMECTOMY;

EID: 84988728361     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000455873.30438.9b     Document Type: Review

References (36)

1. Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms [published online ahead of print January 3, 2014]. J Autoimmun 2014. doi:10.1016/j.jaut.2013.12.011.
2. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116(11):2843-2854.
3. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011;69(2):418-422.
4. Zhang B, Shen C, Bealmear B. Autoantibodies to agrin in myasthenia gravis patients. PLoS One 2014;9(3):e91816.
5. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7(3):365-368.
6. Sanders DB, Massey JM. Clinical features of myasthenia gravis. In:Engel AG, editor. Neuromuscular junction disorders. Philadelphia, PA: Elsevier, 2008:229-252.
7. Sanders DB. Approach to diseases of the neuromuscular junction. In:Tawil R, Venance S, editors. Neuromuscular disorders. London, UK: Wiley-Blackwell, 2011:113-117.
8. Myasthenia Gravis Foundation of America, Inc. www.myasthenia.org. Accessed May 20, 2014.
9. Pascuzzi RM. The edrophonium test. Semin Neurol 2003;23(1):83-88.
10. Ing EB, Ing SY, Ing T, Ramocki JA. The complication rate of edrophonium testing for suspected myasthenia gravis. Can J Ophthalmol 2005;35(3):141-144.
11. Rostedt Punga A, Stålberg EV. Acetylcholinesterase inhibitors in MG: to be or not to be? Muscle Nerve 2009;39(6):724-728.
12. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004;10(21):7270-7275.
13. Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L; Muscle Study Group. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve 2014;49(4):483-486.
14. DeCroos EC, Hobson-Webb LD, Juel VC, et al. Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis? Muscle Nerve 2013;49(1):30-34.
15. Sanders DB. Measuring jitter with concentric needle electrodes. Muscle Nerve 2013;47(3):317-318.
16. Stålberg EV, Trontelj JV, Sanders DB. Myasthenia gravis and other disorders of neuromuscular transmission. Single fiber EMG. Fiskebäckskil, Sweden: Edshagen Publishing House, 2010:218-266.
17. Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 2005;116(9):2065-2068.
18. Marx A, Wilisch A, Schultz A, et al. Pathogenesis of myasthenia gravis. Virchows Arch 1997;430(5):355-364.
19. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55(1):7-15.
20. Aban IB, Wolfe GI, Cutter GR, et al; MGTX Advisory Committee. The MGTX experience: challenges in planning and executing an international, multicenter clinical trial. J Neuroimmunol 2008;202:80-84.
21. Margaritora S, Cesario A, Cusumano G, et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010;89(1):245-252.
22. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71(6):394-395.
23. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71(6):400-4006.
24. Hehir MK, Burns TM, Alpers JP, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010; 41(5):593-598.
25. Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity 2010;43(5-6):428-435.
26. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011;44(1):36-40.
27. Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 2013; 12(9):931-935.
28. Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012;78(3):189-193.
29. Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010;23(5):530-535.
30. Chalk CH, Murray NM, Newsom-Davis J, et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990;40(10):1552-1556.
31. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321(23):1567-1571.
32. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2003;(2):CD003279.
33. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000;54(3):603-607.
34. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome. Electrodiagnostic findings and response to treatment. Neurology 2000;54(11):2176-2178.
35. Maddison P. Treatment in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 2012;1275:78-84.
36. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82(6):671-673.